<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555151</url>
  </required_header>
  <id_info>
    <org_study_id>CQMF149E2201</org_study_id>
    <secondary_id>2011-005100-14</secondary_id>
    <nct_id>NCT01555151</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy, safety and pharmacokinetics of
      Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and
      adolescent patients with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 29</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on day 29 after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) After Days 8, 15 and 22 of Treatment</measure>
    <time_frame>Days 8, 15 and 22</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on days 8, 15 and 22 after treatment. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at All Time Points</measure>
    <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
    <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data within 6 hr of rescue medication use is excluded from this analysis. Mixed model: FVC = treatment + gender+ baseline FVC + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow Between 25% and 75% (FEF25-75%) at All Time Points</measure>
    <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
    <description>The Forced Expiratory Flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second Forced Vital Capacity (FEV1/FVC) Percent at All Time Points</measure>
    <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 4 Weeks of Treatment</measure>
    <time_frame>Baseline and week 4</time_frame>
    <description>Peak expiratory flow rate (PEFR) was measured via electronice Peak flow meter by patient at home. Mixed model used: change from baseline in the mean evening PEFR = treatment + age + gender + baseline evening PEFR + level of asthma control + region + center (region)+ error. Center is included as a random effect nested within region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire (ACQ-5) by Visit</measure>
    <time_frame>Baseline, days 8,15,22 and 29</time_frame>
    <description>Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ-5 has five questions of the asthma symptoms to be answered by the patient. The overall score is the average of the 5 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region. - Baseline ACQ-5 is defined as the questionnaire completed on Day 1 (randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over 4 Weeks of Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Rescue medication data recorded during the 14 day run-in period is used to calculate the baseline. - Total number of puffs of rescue medication per day over the full 4 weeks is calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the subject. - MIXED model: Change = treatment + gender + baseline mean daily number of puffs + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With no Rescue Medication Use Over 4 Weeks of Treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mixed model used: percentage of days with no rescue medication use = treatment + age + gender + baseline percentage of days with no rescue use + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.
A day with no rescue use is defined from diary data as any day where the subject does not use any puffs of rescue medication.
The total number of days with no rescue use over the 4 week treatment period is divided by the total number of evaluable days in order to derive the percentage of days with no rescue use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Exhaled Nitric Oxide (FeNO)</measure>
    <time_frame>Days 15 and 29</time_frame>
    <description>FeNO is widely accepted as a non-invasive marker for airway inflammation such as asthma and conducted according to published guideline. FeNO was measured on days 15 and 29 after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cortisol Concentrations</measure>
    <time_frame>Baseline, days 1 and 28</time_frame>
    <description>Blood samples were taken from each subject participating in the study post dose at day 1 and week 4. Cortisol concentrations were evaluated. Results are presented as nmol/L</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">739</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Mometasone furoate 80 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate 200 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate 320 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate 800 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device</description>
    <arm_group_label>Mometasone furoate 80 μg</arm_group_label>
    <arm_group_label>Mometasone furoate 200 µg</arm_group_label>
    <arm_group_label>Mometasone furoate 320 µg</arm_group_label>
    <arm_group_label>Mometasone furoate 800 µg</arm_group_label>
    <other_name>QMF149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Concept 1</intervention_name>
    <description>A single dose dry powder inhaler (SDDPI)</description>
    <arm_group_label>Mometasone furoate 80 μg</arm_group_label>
    <arm_group_label>Mometasone furoate 320 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Twisthaler</intervention_name>
    <description>A single dose dry powder inhaler (SDDPI)</description>
    <arm_group_label>Mometasone furoate 200 µg</arm_group_label>
    <arm_group_label>Mometasone furoate 800 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females who were ≥ 12 years old at the time informed consent was obtained

          -  Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who
             additionally met the following criteria

          -  Patients who were receiving ICS treatment up to the maximum dose per day as indicated
             in the corresponding package leaflet and also a stable ICS regimen for at least 4
             weeks prior to screening (Visit 2).

          -  Patients whose level of asthma control according to GINA 2010 guideline was &quot;Partly
             Controlled&quot; or &quot;Uncontrolled&quot; at screening (Visit 2).

          -  Patients with a pre-bronchodilator FEV1 value of ≤ 80% of predicted normal value at
             screening (Visit 2).

          -  Patients who demonstrated an increase of ≥ 12% and 200 mL in FEV1 over
             prebronchodilator value within 30 minutes after inhalation of 400 μg of salbutamol
             (360 μg of albuterol) at Visit 2 or between Visit 2 and Visit 5.

          -  Patients who were confirmed as &quot;ICS sensitive&quot; by ACQ-5 and FEV1 at Visit 5.

        Key exclusion criteria included:

          -  Patients diagnosed with COPD as defined by the Global Initiative for Chronic
             Obstructive Lung Disease, updated 2010.

          -  Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed
             by chest X-ray to be no longer active), or clinically significant bronchiectasis.

          -  Patients with any chronic conditions affecting the respiratory tract (e.g., chronic
             sinusitis) or chronic lung diseases, which in the opinion of the investigator may
             interfere with the study evaluation or optimal participation in the study.

          -  Patients with seasonal allergy which is likely to deteriorate his/her asthma condition
             during the study period judged by the investigator.

          -  Patients who have had a severe asthma attack/exacerbation requiring hospitalization in
             the 6 months prior to Visit 1 or any time between Visit 1 and Visit 5 must discontinue
             from the trial (screening failure).

          -  Patients who have had an emergency room visit for an asthma attack/exacerbation within
             4 weeks prior to Visit 1 or any time between Visit 1 and Visit 5 must discontinue from
             the trial (screening failure).

          -  Patients who have ever required intubation for a severe asthma attack/exacerbation.

          -  Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1,
             or any time between Visit 1 and Visit 5 must discontinue from the trial (screening
             failure).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2G 1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kohtla-Järve</city>
        <zip>30321</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10696</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>4207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1041</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kistelek</city>
        <zip>6760</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Makó</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mohacs</city>
        <zip>7700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monor</city>
        <zip>2200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szikszo</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Százhalombatta</city>
        <zip>2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 045.</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karamsad</city>
        <zip>388225</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thrissur</city>
        <zip>680002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toon-shi</city>
        <state>Ehime</state>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mizunami-city</city>
        <state>Gifu</state>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <zip>720-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitahiroshima-shi</city>
        <state>Hokkaido</state>
        <zip>061-1121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro-shi</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro-shi</city>
        <state>Hokkaido</state>
        <zip>080-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>004-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>065-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <zip>053-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>653-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki-city</city>
        <state>Okayama</state>
        <zip>712-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>713-8103</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakai-city</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyonaka-city</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rezekne</city>
        <state>LV</state>
        <zip>LV-4600</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talsi</city>
        <state>LV</state>
        <zip>LV3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LT</state>
        <zip>44320</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <state>LT</state>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almere</city>
        <state>The Netherlands</state>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <state>The Netherlands</state>
        <zip>5616GB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiderdorp</city>
        <state>The Netherlands</state>
        <zip>2352 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <state>The Netherlands</state>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zoetermeer</city>
        <state>The Netherlands</state>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geleen</city>
        <zip>6166 GR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-445</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-445</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Nizhny Novgorod</state>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Russia</state>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <state>Russia</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sankt-Peterburg</city>
        <state>Russia</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Russia</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <state>Slovak Republic</state>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <state>Slovak republic</state>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <state>Slovak Republic</state>
        <zip>033 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <state>Slovak Republic</state>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roznava</city>
        <state>Slovak Republic</state>
        <zip>4801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surany</city>
        <state>Slovak Republic</state>
        <zip>942 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trencin</city>
        <state>Slovak Republic</state>
        <zip>91108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>05845</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruzomberok</city>
        <zip>034 26</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rajathevee</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratchathewi</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talas / Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49066</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61098</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>1004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>4050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>20129</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>July 6, 2014</results_first_submitted>
  <results_first_submitted_qc>July 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
        </group>
        <group group_id="P2">
          <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
        </group>
        <group group_id="P3">
          <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
        </group>
        <group group_id="P4">
          <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="184"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="183"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
        </group>
        <group group_id="B2">
          <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
        </group>
        <group group_id="B3">
          <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
        </group>
        <group group_id="B4">
          <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="184"/>
            <count group_id="B4" value="186"/>
            <count group_id="B5" value="739"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="16.33"/>
                    <measurement group_id="B2" value="45.9" spread="15.56"/>
                    <measurement group_id="B3" value="46.0" spread="16.18"/>
                    <measurement group_id="B4" value="45.5" spread="16.57"/>
                    <measurement group_id="B5" value="45.4" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on day 29 after treatment.</description>
        <time_frame>Day 29</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on day 29 after treatment.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.139" spread="0.0281"/>
                    <measurement group_id="O2" value="2.071" spread="0.0283"/>
                    <measurement group_id="O3" value="2.187" spread="0.0281"/>
                    <measurement group_id="O4" value="2.162" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) After Days 8, 15 and 22 of Treatment</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on days 8, 15 and 22 after treatment. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
        <time_frame>Days 8, 15 and 22</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) After Days 8, 15 and 22 of Treatment</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on days 8, 15 and 22 after treatment. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (n=178,173,181,181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.069" spread="0.0252"/>
                    <measurement group_id="O2" value="2.057" spread="0.0253"/>
                    <measurement group_id="O3" value="2.113" spread="0.0251"/>
                    <measurement group_id="O4" value="2.111" spread="0.0250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=179,171,177,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.095" spread="0.0254"/>
                    <measurement group_id="O2" value="2.048" spread="0.0258"/>
                    <measurement group_id="O3" value="2.134" spread="0.0257"/>
                    <measurement group_id="O4" value="2.135" spread="0.0255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=174,170,177,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.126" spread="0.0284"/>
                    <measurement group_id="O2" value="2.071" spread="0.0286"/>
                    <measurement group_id="O3" value="2.175" spread="0.0283"/>
                    <measurement group_id="O4" value="2.146" spread="0.0282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at All Time Points</title>
        <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data within 6 hr of rescue medication use is excluded from this analysis. Mixed model: FVC = treatment + gender+ baseline FVC + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
        <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at All Time Points</title>
          <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data within 6 hr of rescue medication use is excluded from this analysis. Mixed model: FVC = treatment + gender+ baseline FVC + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1/30 min post-dose (n=172,172,175,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.892" spread="0.0208"/>
                    <measurement group_id="O2" value="2.893" spread="0.0207"/>
                    <measurement group_id="O3" value="2.861" spread="0.0209"/>
                    <measurement group_id="O4" value="2.897" spread="0.0208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/1 hr post-dose (n=178,169,174,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.930" spread="0.0234"/>
                    <measurement group_id="O2" value="2.913" spread="0.0238"/>
                    <measurement group_id="O3" value="2.943" spread="0.0238"/>
                    <measurement group_id="O4" value="2.946" spread="0.0235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/50 min pre-dose (n=174,171,179,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.111" spread="0.0325"/>
                    <measurement group_id="O2" value="3.096" spread="0.0325"/>
                    <measurement group_id="O3" value="3.134" spread="0.0321"/>
                    <measurement group_id="O4" value="3.139" spread="0.0324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/15 min pre-dose (n=176,172,179,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.099" spread="0.0324"/>
                    <measurement group_id="O2" value="3.074" spread="0.0324"/>
                    <measurement group_id="O3" value="3.121" spread="0.0321"/>
                    <measurement group_id="O4" value="3.125" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 /50 min pre-dose (n=175,169,170,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.134" spread="0.0342"/>
                    <measurement group_id="O2" value="3.090" spread="0.0347"/>
                    <measurement group_id="O3" value="3.168" spread="0.0348"/>
                    <measurement group_id="O4" value="3.155" spread="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15/15 min pre-dose (n=176,168,176,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.109" spread="0.0343"/>
                    <measurement group_id="O2" value="3.076" spread="0.0348"/>
                    <measurement group_id="O3" value="3.137" spread="0.0345"/>
                    <measurement group_id="O4" value="3.127" spread="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/50 min pre-dose (n=172,167,174,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.136" spread="0.0356"/>
                    <measurement group_id="O2" value="3.091" spread="0.0359"/>
                    <measurement group_id="O3" value="3.203" spread="0.0355"/>
                    <measurement group_id="O4" value="3.152" spread="0.0357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/15 min pre-dose (n=169,170,174,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.134" spread="0.0365"/>
                    <measurement group_id="O2" value="3.096" spread="0.0363"/>
                    <measurement group_id="O3" value="3.198" spread="0.0362"/>
                    <measurement group_id="O4" value="3.157" spread="0.0361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/50 min pre-dose (n=172,168,176,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.146" spread="0.0342"/>
                    <measurement group_id="O2" value="3.115" spread="0.0345"/>
                    <measurement group_id="O3" value="3.184" spread="0.0340"/>
                    <measurement group_id="O4" value="3.180" spread="0.0342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/15 min pre-dose (n=170,165,174, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.135" spread="0.0345"/>
                    <measurement group_id="O2" value="3.095" spread="0.0348"/>
                    <measurement group_id="O3" value="3.153" spread="0.0343"/>
                    <measurement group_id="O4" value="3.161" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=175,166,174,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.132" spread="0.0341"/>
                    <measurement group_id="O2" value="3.092" spread="0.0346"/>
                    <measurement group_id="O3" value="3.151" spread="0.0343"/>
                    <measurement group_id="O4" value="3.184" spread="0.0343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=173,167,172,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.140" spread="0.0351"/>
                    <measurement group_id="O2" value="3.084" spread="0.0353"/>
                    <measurement group_id="O3" value="3.158" spread="0.0353"/>
                    <measurement group_id="O4" value="3.161" spread="0.0350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 10 min post-dose (n=173,162,172,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.160" spread="0.0342"/>
                    <measurement group_id="O2" value="3.113" spread="0.0348"/>
                    <measurement group_id="O3" value="3.216" spread="0.0343"/>
                    <measurement group_id="O4" value="3.194" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 45 min post-dose (n=172,161, 175,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.165" spread="0.0355"/>
                    <measurement group_id="O2" value="3.090" spread="0.0363"/>
                    <measurement group_id="O3" value="3.192" spread="0.0353"/>
                    <measurement group_id="O4" value="3.158" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow Between 25% and 75% (FEF25-75%) at All Time Points</title>
        <description>The Forced Expiratory Flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
        <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow Between 25% and 75% (FEF25-75%) at All Time Points</title>
          <description>The Forced Expiratory Flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Liters per second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1/30 min post-dose (n=172,172,175,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.308" spread="0.0181"/>
                    <measurement group_id="O2" value="1.300" spread="0.0182"/>
                    <measurement group_id="O3" value="1.309" spread="0.0182"/>
                    <measurement group_id="O4" value="1.308" spread="0.0182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/1 hr post-dose (n=178,169,174,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.337" spread="0.0197"/>
                    <measurement group_id="O2" value="1.327" spread="0.0201"/>
                    <measurement group_id="O3" value="1.316" spread="0.0201"/>
                    <measurement group_id="O4" value="1.345" spread="0.0199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/50 min pre-dose (n=173,171,179,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.457" spread="0.0323"/>
                    <measurement group_id="O2" value="1.449" spread="0.0322"/>
                    <measurement group_id="O3" value="1.519" spread="0.0317"/>
                    <measurement group_id="O4" value="1.525" spread="0.0321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/15 min pre-dose (n=175,172,179,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.458" spread="0.0329"/>
                    <measurement group_id="O2" value="1.466" spread="0.0328"/>
                    <measurement group_id="O3" value="1.542" spread="0.0325"/>
                    <measurement group_id="O4" value="1.566" spread="0.0328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 /50 min pre-dose (n=175,169,170,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.509" spread="0.0317"/>
                    <measurement group_id="O2" value="1.430" spread="0.0321"/>
                    <measurement group_id="O3" value="1.514" spread="0.0320"/>
                    <measurement group_id="O4" value="1.544" spread="0.0321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15/15 min pre-dose (n=175,168,176,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.0322"/>
                    <measurement group_id="O2" value="1.414" spread="0.0326"/>
                    <measurement group_id="O3" value="1.520" spread="0.0321"/>
                    <measurement group_id="O4" value="1.561" spread="0.0327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/50 min pre-dose (n=171,167,174,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.511" spread="0.0350"/>
                    <measurement group_id="O2" value="1.440" spread="0.0353"/>
                    <measurement group_id="O3" value="1.565" spread="0.0348"/>
                    <measurement group_id="O4" value="1.555" spread="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/15 min pre-dose (n=168,170,174,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.540" spread="0.0365"/>
                    <measurement group_id="O2" value="1.476" spread="0.0362"/>
                    <measurement group_id="O3" value="1.600" spread="0.0361"/>
                    <measurement group_id="O4" value="1.591" spread="0.0361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/50 min pre-dose (n=171,168,176,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" spread="0.0353"/>
                    <measurement group_id="O2" value="1.458" spread="0.0354"/>
                    <measurement group_id="O3" value="1.581" spread="0.0350"/>
                    <measurement group_id="O4" value="1.598" spread="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/15 min pre-dose (n=169,165,174, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" spread="0.0357"/>
                    <measurement group_id="O2" value="1.481" spread="0.0359"/>
                    <measurement group_id="O3" value="1.574" spread="0.0354"/>
                    <measurement group_id="O4" value="1.584" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=175,166,174,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.558" spread="0.0362"/>
                    <measurement group_id="O2" value="1.457" spread="0.0368"/>
                    <measurement group_id="O3" value="1.557" spread="0.0364"/>
                    <measurement group_id="O4" value="1.615" spread="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=172,167,172,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.566" spread="0.0367"/>
                    <measurement group_id="O2" value="1.460" spread="0.0369"/>
                    <measurement group_id="O3" value="1.577" spread="0.0368"/>
                    <measurement group_id="O4" value="1.593" spread="0.0365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 10 min post-dose (n=172,162,172,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.537" spread="0.0369"/>
                    <measurement group_id="O2" value="1.451" spread="0.0376"/>
                    <measurement group_id="O3" value="1.604" spread="0.0369"/>
                    <measurement group_id="O4" value="1.584" spread="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 45 min post-dose (n=171,161, 175,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="0.0370"/>
                    <measurement group_id="O2" value="1.438" spread="0.0378"/>
                    <measurement group_id="O3" value="1.576" spread="0.0366"/>
                    <measurement group_id="O4" value="1.571" spread="0.0369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second Forced Vital Capacity (FEV1/FVC) Percent at All Time Points</title>
        <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
        <time_frame>Days 1, 8, 15, 22, 28 and 29 at all time points</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second Forced Vital Capacity (FEV1/FVC) Percent at All Time Points</title>
          <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. Data within 6 hr of rescue medication use is excluded from this analysis.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1/30 min post-dose (n=172,172,175,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.043" spread="0.2548"/>
                    <measurement group_id="O2" value="64.898" spread="0.2556"/>
                    <measurement group_id="O3" value="65.184" spread="0.2559"/>
                    <measurement group_id="O4" value="64.898" spread="0.2554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/1 hr post-dose (n=178,169,174,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.177" spread="0.2833"/>
                    <measurement group_id="O2" value="64.833" spread="0.2890"/>
                    <measurement group_id="O3" value="65.005" spread="0.2885"/>
                    <measurement group_id="O4" value="65.072" spread="0.2845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/50 min pre-dose (n=174,171,179,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.566" spread="0.4281"/>
                    <measurement group_id="O2" value="66.301" spread="0.4286"/>
                    <measurement group_id="O3" value="67.344" spread="0.4222"/>
                    <measurement group_id="O4" value="66.568" spread="0.4264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8/15 min pre-dose (n=176,172,179,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.595" spread="0.4259"/>
                    <measurement group_id="O2" value="66.790" spread="0.4262"/>
                    <measurement group_id="O3" value="67.778" spread="0.4224"/>
                    <measurement group_id="O4" value="67.156" spread="0.4252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 /50 min pre-dose (n=176,169,170,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.007" spread="0.4329"/>
                    <measurement group_id="O2" value="66.122" spread="0.4398"/>
                    <measurement group_id="O3" value="67.487" spread="0.4395"/>
                    <measurement group_id="O4" value="67.139" spread="0.4407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15/15 min pre-dose (n=176,168,176,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.878" spread="0.4370"/>
                    <measurement group_id="O2" value="66.006" spread="0.4443"/>
                    <measurement group_id="O3" value="67.607" spread="0.4384"/>
                    <measurement group_id="O4" value="67.514" spread="0.4456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/50 min pre-dose (n=172,167,174,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.081" spread="0.4594"/>
                    <measurement group_id="O2" value="66.567" spread="0.4643"/>
                    <measurement group_id="O3" value="67.831" spread="0.4584"/>
                    <measurement group_id="O4" value="67.742" spread="0.4615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22/15 min pre-dose (n=169,170,174,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.403" spread="0.4657"/>
                    <measurement group_id="O2" value="66.885" spread="0.4629"/>
                    <measurement group_id="O3" value="68.143" spread="0.4622"/>
                    <measurement group_id="O4" value="67.895" spread="0.4612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/50 min pre-dose (n=172,168,176,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.128" spread="0.4584"/>
                    <measurement group_id="O2" value="66.835" spread="0.4615"/>
                    <measurement group_id="O3" value="68.124" spread="0.4567"/>
                    <measurement group_id="O4" value="67.810" spread="0.4578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/15 min pre-dose (n=170,165,174, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.503" spread="0.4813"/>
                    <measurement group_id="O2" value="67.296" spread="0.4854"/>
                    <measurement group_id="O3" value="68.255" spread="0.4796"/>
                    <measurement group_id="O4" value="67.878" spread="0.4804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=175,166,174,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.700" spread="0.4723"/>
                    <measurement group_id="O2" value="67.013" spread="0.4796"/>
                    <measurement group_id="O3" value="68.031" spread="0.4755"/>
                    <measurement group_id="O4" value="68.126" spread="0.4755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/30 min post-dose (n=173,167,172,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.945" spread="0.4703"/>
                    <measurement group_id="O2" value="66.832" spread="0.4741"/>
                    <measurement group_id="O3" value="68.243" spread="0.4736"/>
                    <measurement group_id="O4" value="68.057" spread="0.4698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 10 min post-dose (n=173,162,172,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.427" spread="0.4639"/>
                    <measurement group_id="O2" value="66.711" spread="0.4736"/>
                    <measurement group_id="O3" value="68.265" spread="0.4654"/>
                    <measurement group_id="O4" value="67.592" spread="0.4676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/23hr 45 min post-dose (n=172,161, 175,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.630" spread="0.4694"/>
                    <measurement group_id="O2" value="66.541" spread="0.4806"/>
                    <measurement group_id="O3" value="67.961" spread="0.4667"/>
                    <measurement group_id="O4" value="67.831" spread="0.4692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 4 Weeks of Treatment</title>
        <description>Peak expiratory flow rate (PEFR) was measured via electronice Peak flow meter by patient at home. Mixed model used: change from baseline in the mean evening PEFR = treatment + age + gender + baseline evening PEFR + level of asthma control + region + center (region)+ error. Center is included as a random effect nested within region.</description>
        <time_frame>Baseline and week 4</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 4 Weeks of Treatment</title>
          <description>Peak expiratory flow rate (PEFR) was measured via electronice Peak flow meter by patient at home. Mixed model used: change from baseline in the mean evening PEFR = treatment + age + gender + baseline evening PEFR + level of asthma control + region + center (region)+ error. Center is included as a random effect nested within region.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Liters per min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning 4 wks-baseline (n=177,171, 175, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.952" spread="4.1929"/>
                    <measurement group_id="O2" value="3.955" spread="4.2616"/>
                    <measurement group_id="O3" value="2.785" spread="4.2349"/>
                    <measurement group_id="O4" value="1.606" spread="4.1464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 4 wks-baseline (n=176, 172, 174, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.354" spread="3.9003"/>
                    <measurement group_id="O2" value="0.293" spread="3.9477"/>
                    <measurement group_id="O3" value="-0.644" spread="3.9427"/>
                    <measurement group_id="O4" value="6.287" spread="3.8826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) by Visit</title>
        <description>Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ-5 has five questions of the asthma symptoms to be answered by the patient. The overall score is the average of the 5 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region. - Baseline ACQ-5 is defined as the questionnaire completed on Day 1 (randomization).</description>
        <time_frame>Baseline, days 8,15,22 and 29</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) by Visit</title>
          <description>Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ-5 has five questions of the asthma symptoms to be answered by the patient. The overall score is the average of the 5 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region. - Baseline ACQ-5 is defined as the questionnaire completed on Day 1 (randomization).</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8-baseline (n=179,176,182,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.662" spread="0.0543"/>
                    <measurement group_id="O2" value="-0.730" spread="0.0546"/>
                    <measurement group_id="O3" value="-0.908" spread="0.0540"/>
                    <measurement group_id="O4" value="-0.890" spread="0.0538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15-baseline(n=180,174,179,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.899" spread="0.0590"/>
                    <measurement group_id="O2" value="-0.908" spread="0.0599"/>
                    <measurement group_id="O3" value="-1.117" spread="0.0595"/>
                    <measurement group_id="O4" value="-0.973" spread="0.0593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22-baseline (n=178,173,178,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.994" spread="0.0620"/>
                    <measurement group_id="O2" value="-0.982" spread="0.0628"/>
                    <measurement group_id="O3" value="-1.262" spread="0.0622"/>
                    <measurement group_id="O4" value="-1.097" spread="0.0622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29-baseline (n=179,176,181,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.079" spread="0.0630"/>
                    <measurement group_id="O2" value="-1.109" spread="0.602"/>
                    <measurement group_id="O3" value="-1.329" spread="0.0632"/>
                    <measurement group_id="O4" value="-1.162" spread="0.0625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over 4 Weeks of Treatment</title>
        <description>Rescue medication data recorded during the 14 day run-in period is used to calculate the baseline. - Total number of puffs of rescue medication per day over the full 4 weeks is calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the subject. - MIXED model: Change = treatment + gender + baseline mean daily number of puffs + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over 4 Weeks of Treatment</title>
          <description>Rescue medication data recorded during the 14 day run-in period is used to calculate the baseline. - Total number of puffs of rescue medication per day over the full 4 weeks is calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the subject. - MIXED model: Change = treatment + gender + baseline mean daily number of puffs + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.456" spread="0.0972"/>
                    <measurement group_id="O2" value="-0.391" spread="0.0985"/>
                    <measurement group_id="O3" value="-0.600" spread="0.0981"/>
                    <measurement group_id="O4" value="-0.677" spread="0.0963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With no Rescue Medication Use Over 4 Weeks of Treatment</title>
        <description>Mixed model used: percentage of days with no rescue medication use = treatment + age + gender + baseline percentage of days with no rescue use + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.
A day with no rescue use is defined from diary data as any day where the subject does not use any puffs of rescue medication.
The total number of days with no rescue use over the 4 week treatment period is divided by the total number of evaluable days in order to derive the percentage of days with no rescue use.</description>
        <time_frame>4 weeks</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With no Rescue Medication Use Over 4 Weeks of Treatment</title>
          <description>Mixed model used: percentage of days with no rescue medication use = treatment + age + gender + baseline percentage of days with no rescue use + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.
A day with no rescue use is defined from diary data as any day where the subject does not use any puffs of rescue medication.
The total number of days with no rescue use over the 4 week treatment period is divided by the total number of evaluable days in order to derive the percentage of days with no rescue use.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>percentage days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.148" spread="2.2576"/>
                    <measurement group_id="O2" value="75.236" spread="2.3291"/>
                    <measurement group_id="O3" value="75.157" spread="2.3044"/>
                    <measurement group_id="O4" value="80.578" spread="2.3476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Exhaled Nitric Oxide (FeNO)</title>
        <description>FeNO is widely accepted as a non-invasive marker for airway inflammation such as asthma and conducted according to published guideline. FeNO was measured on days 15 and 29 after treatment.</description>
        <time_frame>Days 15 and 29</time_frame>
        <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Exhaled Nitric Oxide (FeNO)</title>
          <description>FeNO is widely accepted as a non-invasive marker for airway inflammation such as asthma and conducted according to published guideline. FeNO was measured on days 15 and 29 after treatment.</description>
          <population>The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug with available data for analysis.</population>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n= 142, 139, 139, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.286" spread="1.2983"/>
                    <measurement group_id="O2" value="26.762" spread="1.3201"/>
                    <measurement group_id="O3" value="19.098" spread="1.3246"/>
                    <measurement group_id="O4" value="21.017" spread="1.2911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=141, 143, 145, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.777" spread="1.3078"/>
                    <measurement group_id="O2" value="27.055" spread="1.3035"/>
                    <measurement group_id="O3" value="18.468" spread="1.2952"/>
                    <measurement group_id="O4" value="19.981" spread="1.2803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cortisol Concentrations</title>
        <description>Blood samples were taken from each subject participating in the study post dose at day 1 and week 4. Cortisol concentrations were evaluated. Results are presented as nmol/L</description>
        <time_frame>Baseline, days 1 and 28</time_frame>
        <population>The safety set includes all subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
            <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
            <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cortisol Concentrations</title>
          <description>Blood samples were taken from each subject participating in the study post dose at day 1 and week 4. Cortisol concentrations were evaluated. Results are presented as nmol/L</description>
          <population>The safety set includes all subjects who received at least one dose of study drug.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 183, 178, 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.040" spread="80.3928"/>
                    <measurement group_id="O2" value="143.132" spread="88.4206"/>
                    <measurement group_id="O3" value="143.791" spread="85.8696"/>
                    <measurement group_id="O4" value="150.108" spread="88.6815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/1 Hr (n=179, 177,174, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.130" spread="92.7539"/>
                    <measurement group_id="O2" value="106.965" spread="81.5160"/>
                    <measurement group_id="O3" value="107.526" spread="74.3770"/>
                    <measurement group_id="O4" value="115.489" spread="79.3869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/-25 Mins (n= 172, 169, 174, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.760" spread="73.3567"/>
                    <measurement group_id="O2" value="140.604" spread="72.8885"/>
                    <measurement group_id="O3" value="143.555" spread="82.4961"/>
                    <measurement group_id="O4" value="145.484" spread="92.2940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/1 Hr (n= 172, 168, 174, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.399" spread="68.9416"/>
                    <measurement group_id="O2" value="107.931" spread="70.7374"/>
                    <measurement group_id="O3" value="105.468" spread="57.9029"/>
                    <measurement group_id="O4" value="110.477" spread="77.2220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate 80 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 80 μg daily in the evening</description>
        </group>
        <group group_id="E2">
          <title>Mometasone Furoate 200 ug Daily Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 200 μg daily in the evening</description>
        </group>
        <group group_id="E3">
          <title>Mometasone Furoate 320 ug Daily Via the Concept1 Device</title>
          <description>Mometasone furoate (MF) delivered via Concept1, 320 μg daily in the evening</description>
        </group>
        <group group_id="E4">
          <title>Mometasone Furoate 800 ug Via the Twisthaler® Device</title>
          <description>Mometasone furoate delivered via Twisthaler®, 800 μg daily in the evening</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="735"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1(862)778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

